Talen Energy Corp V.TLN

Primary Symbol: TLN

Talen Energy Corporation owns and operates power infrastructure in the United States. The Company produces and sells electricity, capacity, and ancillary services in wholesale power markets in the United States, primarily in PJM and WECC, with its generation fleet principally located in the Mid-Atlantic region of the United States and Montana. The majority of its generation is produced at its zero-carbon nuclear and lower-carbon gas-fired facilities. Its generation capacity is 10,665 megawatts (MW). Its segments include PJM and Other. The PJM segment is engaged in electricity generation, marketing activities, commodity risk and fuel management within the PJM RTO or ISO markets and comprises Susquehanna and Talen’s natural gas and coal generation facilities. Its Other segment includes the operating and marketing activities of Talen Montana’s proportionate share of the Colstrip Units in the WECC market, the operating activities of Nautilus, and other development activities.

NDAQ:TLN - Post by User

Talen Energy Corp

Bullboard Posts

Post by Everswanon Apr 24, 2009 7:02am

105 Views

Post# 15941349

Roche fights back Astra!!! NEWSSS

Check this out:
https://www.reuters.com/article/rbssHealthcareNews/idUSLO18352620090424

thallion's poster
https://www.thallion.com/docs/publications/26.AACR09-Batist-Web.pdf

Roche is not letting this market go away.
Astra will be forced to buy TLN

From poster:

TLN-4601 is a promising candidate for cancer treatment in combination with TKIs. It is efficacious in the presence of the EGFr L858R mutation, highly expressed in Asian patients with lung cancer.
Moreover, it can increase TKIs effect, especially erlotinib, and overcomes not only T790M -induced resistance, but also K-RAS-induced resistant

If Astra buys TLN it gains access to EGFr L858R mutations market as a leader, 3% of Asian population makes a huge market. There is lots more asian than white people.

Also, Astra would gain advantage to T790 mutations

Also, KRAS mutation markte.

If Roche is not bidding for TLN, it will be second during the 2nd generation drug.

Hummm.... All those analysts are missing TLN from their RADAR screen. It will be short and sweet when the market reacts.

Bullboard Posts

Level up your trading with BMO InvestorLine’s enhanced features